Evidence map›Paper›PMID 38612539›Full record

ArticleInternational journal of molecular sciences2024

Inflammasome-Related Genetic Polymorphisms as Severity Biomarkers of COVID-19.

Verónica Pulito-Cueto, María Sebastián Mora-Gil, Diego Ferrer-Pargada, Sara Remuzgo-Martínez, Fernanda Genre, Leticia Lera-Gómez, Pilar Alonso-Lecue, Joao Carlos Batista-Liz, Sandra Tello-Mena, Beatriz Abascal-Bolado and 7 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Special Issue "Molecular Advances and Perspectives of Lung Disease".International journal of molecular sciences · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Verónica Pulito-CuetoImmunopathology Group, Marqués de Valdecilla University Hospital-Valdecilla Research Institute (IDIVAL), 39008 Santander, Spain.ORCID 0000-0002-3534-8467
María Sebastián Mora-GilImmunopathology Group, Marqués de Valdecilla University Hospital-Valdecilla Research Institute (IDIVAL), 39008 Santander, Spain.
Diego Ferrer-PargadaDepartment of Pneumology, Marqués de Valdecilla University Hospital, 39008 Santander, Spain.ORCID 0000-0001-9088-5946
Sara Remuzgo-MartínezValdecilla Research Institute (IDIVAL), 39011 Santander, Spain.ORCID 0000-0003-4455-7241
Fernanda GenreValdecilla Research Institute (IDIVAL), 39011 Santander, Spain.
Leticia Lera-GómezDepartment of Microbiology, Marqués de Valdecilla University Hospital, 39008 Santander, Spain.
Pilar Alonso-LecueImmunopathology Group, Marqués de Valdecilla University Hospital-Valdecilla Research Institute (IDIVAL), 39008 Santander, Spain.
Joao Carlos Batista-LizImmunopathology Group, Marqués de Valdecilla University Hospital-Valdecilla Research Institute (IDIVAL), 39008 Santander, Spain.
Sandra Tello-MenaDepartment of Pneumology, Marqués de Valdecilla University Hospital, 39008 Santander, Spain.
Beatriz Abascal-BoladoDepartment of Pneumology, Marqués de Valdecilla University Hospital, 39008 Santander, Spain.
Sheila IzquierdoDepartment of Pneumology, Marqués de Valdecilla University Hospital, 39008 Santander, Spain.
Juan José Ruiz-CubillánDepartment of Pneumology, Marqués de Valdecilla University Hospital, 39008 Santander, Spain.
Carlos Armiñanzas-CastilloDepartment of Infectious Diseases, Marqués de Valdecilla University Hospital, 39008 Santander, Spain.
Ricardo BlancoImmunopathology Group, Marqués de Valdecilla University Hospital-Valdecilla Research Institute (IDIVAL), 39008 Santander, Spain.
Miguel A González-GaySchool of Medicine, University of Cantabria, 39011 Santander, Spain.ORCID 0000-0002-7924-7406
Raquel López-MejíasImmunopathology Group, Marqués de Valdecilla University Hospital-Valdecilla Research Institute (IDIVAL), 39008 Santander, Spain.ORCID 0000-0003-0548-2689
José M CifriánImmunopathology Group, Marqués de Valdecilla University Hospital-Valdecilla Research Institute (IDIVAL), 39008 Santander, Spain.
Marqués de Valdecilla University Hospital · ESInstituto de Investigación Marqués de Valdecilla · ESUniversidad de Cantabria · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The most critical forms of coronavirus disease 2019 (COVID-19) are associated with excessive activation of the inflammasome. Despite the COVID-19 impact on public health, we still do not fully understand the mechanisms by which the inflammatory response influences disease prognosis. Accordingly, we aimed to elucidate the role of polymorphisms in the key genes of the formation and signaling of the inflammasome as biomarkers of COVID-19 severity. For this purpose, a large and well-defined cohort of 377 COVID-19 patients with mild (n = 72), moderate (n = 84), severe (n = 100), and critical (n = 121) infections were included. A total of 24 polymorphisms located in inflammasome-related genes (

Indexed as

COVID-19InflammasomesBiomarkersCARD Signaling Adaptor ProteinsCaspase 1HumansNeoplasm ProteinsNLR Family, Pyrin Domain-Containing 3 ProteinPolymorphism, GeneticBiomarkersCARD8 protein, humanCARD Signaling Adaptor ProteinsCaspase 1InflammasomesNeoplasm ProteinsNLR Family, Pyrin Domain-Containing 3 ProteinCOVID-19 severityinflammasomeinflammasome-related polymorphisms

Identifiers

PMID38612539
PMCPMC11011752
OpenAlexW4393218756

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.